Anemia and erythropoietin in heart failure.
Anemia is frequently observed in patients with chronic heart failure (CHF) and is related to an impaired outcome. The origin of anemia in CHF is diverse and is associated with several factors including renal failure, resistance of the bone marrow to erythropoietin (EPO), hematinic deficiencies, and medication use. Recently, several small-scale clinical trials have shown that EPO treatment might improve clinical parameters in anemic heart failure patients. In addition, several preclinical studies have shown that EPO possesses non-hematopoietic effects. This current review focuses on the etiology, consequences, and treatment of anemia in heart failure patients. The pleiotropic effects of EPO in an experimental setting will also be discussed. Heart Fail Monit 2008;6(1):28-33.
van der Meer
Peter
P
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Lipsic
Erik
E
van Gilst
Wiek H
WH
van Veldhuisen
Dirk J
DJ
D000740:Anemia; D001853:Bone Marrow / Q000187:drug effects; D002908:Chronic Disease; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000494:pharmacology; D006333:Heart Failure; D006801:Humans
D004921:Erythropoietin; D000068817:Epoetin Alfa